Biohaven Ltd. (BHVN) Stock Forecast
BHVN analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.18 / 5 from 17 analysts
- Price target
- $21.27 average of analyst targets
- Upside to target
- +97.3% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.80
- 52-week range
- $7.79 – $18.11
BHVN analyst ratings
17 analystsNumber of analysts at each rating.
BHVN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BHVN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.16 | −$0.73 | $1.66 | −$1.47 | +111.2% | 6 |
| Current fiscal year (2026) | −$1.65 | −$2.88 | −$0.09 | −$5.55 | +70.3% | 6 |
| Next fiscal year (2027) | −$1.87 | −$2.62 | −$1.43 | −$1.65 | −13.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BHVN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $50.0M | $0 | $350.0M | 0.0% | 14 |
| Current fiscal year (2026) | $75.0M | $0 | $350.0M | 0.0% | 14 |
| Next fiscal year (2027) | $40.7M | $0 | $162.6M | −45.7% | 14 |
BHVN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BHVN revenue: reported and forecast
BHVN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$0.57 | −$0.21 | $0.16 | $0.16 | −128.7% | 1 up · 2 down |
| Current fiscal year (2026) | −$2.40 | −$2.41 | −$1.97 | −$1.65 | −$1.65 | −31.1% | 1 up · 2 down |
| Next fiscal year (2027) | −$1.95 | −$1.94 | −$1.94 | −$1.87 | −$1.87 | −4.0% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BHVN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BHVN beat in 3 of 12.
What analysts expect from BHVN
17 analysts cover Biohaven; their consensus rating is buy (4.18 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.27, 97.3% above the latest close of $10.78. Analysts expect earnings of −$1.65 per share for 2026, +70.3% from a year earlier. For 2027 the average estimate is −$1.87 per share on revenue of $40.7 million. Biohaven beat the EPS estimate in 3 of the last 12 quarters.
Related: BHVN income statement, BHVN key metrics, BHVN chart. See the BHVN stock overview for the latest quote and news.
BHVN forecast FAQ
What is Biohaven's price target?
The average analyst price target for Biohaven is $21.27, 97.3% above the latest close of $10.78.
Is Biohaven a buy, hold or sell?
Of 17 analysts covering Biohaven, 9 rate it a strong buy, 3 a buy, 4 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Biohaven's EPS forecast?
Analysts forecast −$1.65 per share for 2026 (range −$2.88 to −$0.09); for 2027 the estimate is −$1.87.
What is Biohaven's revenue forecast?
The average revenue estimate for 2026 is $75.0 million, growth of 0.0%; for 2027 it is $40.7 million.
When does Biohaven report earnings?
Biohaven is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.80.
Does Biohaven usually beat earnings estimates?
Biohaven reported EPS at or above the analyst estimate in 3 of the last 12 quarters.